Position Paper: for an ambitious EU industrial strategy

SPC manufacturing waiver

Fighting counterfeit medicines in Europe: the effect on access to medicines

The implementation of the Falsified Medicines Directive, and its Delegated Regulation with detailed specifications of safety features, will provide an additional obstacle for counterfeiters. The implementation of the Directive aims to prevent falsified medicines from reaching patients, and is in the interest of public health. However, the financial burden for manufacturers to implement these additional safety features, as well as the repository system that will allow the verification of authenticity of individual packs of medicine, may threaten the availability of medicines.

Authors

Maarten Van Baelen, Pieter Dylst, Catarina Lopes Pereira, Johan Verhaeghe, Koen Nauwelaerts, Susie Lyddon

Read more

Value Added Medicines: Time to Adjust the HTA Decision Frameworks

Join Medicines for Europe – 2017

Universal Access to Health, How Can We Contribute?

AGENDA

9.30 Coffee & Registration

10.00 Introduction: the event, rationale of the partnership, 4th edition, goal of the debate, setting

Moderator:  Sarantis Michalopoulos, Euractiv

10.15 Welcome Address and MEPs’ perspectives

  • MEP José Inácio Faria, EPP group, PT
  • MEP Andrey Kovatchev, EPP group, BU

10.30 European Commission’s overview

  • Sylvain Giraud, Head of Unit, DG Santé

10.45 Stakeholders’ perspectives on improving access to healthcare

  • Nicola Bedlington (EPF)
  • Arnaud Emériau (ESIP)
  • Yannis Natsis (EPHA)
  • Adrian van den Hoven (Medicines for Europe)

11:45  Exchange of views

12:15  Questions and answers

12.30  Networking Lunch

REGISTRATION

Medicines for Europe – Better Access. Better Health

10th Medicines for Europe Pharmacovigilance Conference. Save the date!

PACT poster

ISPOR 2016 EU – Value Added Medicines

ispor2

Healthcare System Inefficiencies Related To Medicines: Any Potential Room For Improvement?

OPEN

ispor3

Value Added Medicines: The Need to Establish One Common Terminology for Repurposed Medicines

OPEN

ispor4

Value Added Medicines: What Value Repurposed Medicines Might Bring to Society?

OPEN

ispor5

Obstacles for Adoption of Value Added Medicines: Call for Policy Changes for Value Recognition of Repurposed Medicines

OPEN